Boston Scientific Co. (NYSE:BSX) Shares Sold by Royal London Asset Management Ltd.

Royal London Asset Management Ltd. lessened its holdings in shares of Boston Scientific Co. (NYSE:BSX) by 6.0% during the 2nd quarter, according to its most recent disclosure with the SEC. The institutional investor owned 529,347 shares of the medical equipment provider’s stock after selling 34,079 shares during the quarter. Royal London Asset Management Ltd.’s holdings in Boston Scientific were worth $22,743,000 as of its most recent filing with the SEC.

A number of other large investors have also recently modified their holdings of the stock. Whittier Trust Co. raised its holdings in Boston Scientific by 31.5% during the second quarter. Whittier Trust Co. now owns 1,069 shares of the medical equipment provider’s stock worth $46,000 after purchasing an additional 256 shares in the last quarter. Winslow Evans & Crocker Inc. raised its holdings in Boston Scientific by 28.4% during the second quarter. Winslow Evans & Crocker Inc. now owns 1,220 shares of the medical equipment provider’s stock worth $54,000 after purchasing an additional 270 shares in the last quarter. Hanseatic Management Services Inc. raised its holdings in Boston Scientific by 1.4% during the second quarter. Hanseatic Management Services Inc. now owns 20,714 shares of the medical equipment provider’s stock worth $890,000 after purchasing an additional 288 shares in the last quarter. BB&T Corp raised its holdings in Boston Scientific by 0.5% during the second quarter. BB&T Corp now owns 52,968 shares of the medical equipment provider’s stock worth $2,277,000 after purchasing an additional 288 shares in the last quarter. Finally, Nelson Van Denburg & Campbell Wealth Management Group LLC raised its holdings in Boston Scientific by 60.0% during the first quarter. Nelson Van Denburg & Campbell Wealth Management Group LLC now owns 800 shares of the medical equipment provider’s stock worth $30,000 after purchasing an additional 300 shares in the last quarter. 90.60% of the stock is currently owned by hedge funds and other institutional investors.

A number of analysts have weighed in on BSX shares. Needham & Company LLC set a $46.00 price objective on shares of Boston Scientific and gave the stock a “buy” rating in a report on Wednesday, July 24th. Leerink Swann set a $50.00 price objective on shares of Boston Scientific and gave the stock a “buy” rating in a report on Wednesday, July 31st. Stifel Nicolaus raised their price objective on shares of Boston Scientific from $44.00 to $46.00 and gave the stock an “in-line” rating in a report on Thursday, June 27th. Piper Jaffray Companies set a $50.00 price objective on shares of Boston Scientific and gave the stock a “buy” rating in a report on Wednesday, July 24th. Finally, Canaccord Genuity raised their target price on shares of Boston Scientific from $43.00 to $46.00 and gave the stock a “buy” rating in a research report on Thursday, June 27th. Four research analysts have rated the stock with a hold rating, sixteen have issued a buy rating and two have assigned a strong buy rating to the company’s stock. The stock presently has an average rating of “Buy” and an average target price of $44.91.

In related news, SVP Xin Warren Wang sold 10,000 shares of Boston Scientific stock in a transaction on Monday, June 3rd. The shares were sold at an average price of $38.45, for a total value of $384,500.00. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, SVP Jodi Euerle Eddy sold 7,803 shares of Boston Scientific stock in a transaction on Tuesday, May 28th. The shares were sold at an average price of $38.42, for a total transaction of $299,791.26. Following the completion of the transaction, the senior vice president now owns 88,978 shares in the company, valued at $3,418,534.76. The disclosure for this sale can be found here. Over the last quarter, insiders sold 60,327 shares of company stock worth $2,466,666. 0.66% of the stock is currently owned by insiders.

NYSE:BSX traded up $0.58 during midday trading on Tuesday, reaching $42.91. The stock had a trading volume of 1,380,885 shares, compared to its average volume of 5,790,351. The business’s fifty day simple moving average is $42.51. Boston Scientific Co. has a 12-month low of $31.56 and a 12-month high of $43.66. The company has a current ratio of 1.31, a quick ratio of 1.04 and a debt-to-equity ratio of 0.81. The stock has a market cap of $59.17 billion, a PE ratio of 29.19, a P/E/G ratio of 2.59 and a beta of 0.80.

Boston Scientific (NYSE:BSX) last posted its quarterly earnings data on Wednesday, July 24th. The medical equipment provider reported $0.39 earnings per share for the quarter, beating analysts’ consensus estimates of $0.38 by $0.01. Boston Scientific had a net margin of 13.85% and a return on equity of 23.29%. The firm had revenue of $2.63 billion for the quarter, compared to analyst estimates of $2.64 billion. During the same period last year, the firm posted $0.41 EPS. Boston Scientific’s quarterly revenue was up 5.7% on a year-over-year basis. As a group, sell-side analysts expect that Boston Scientific Co. will post 1.56 EPS for the current year.

Boston Scientific Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through three segments: MedSurg, Rhythm and Neuro, and Cardiovascular. The company offers interventional cardiology products, including drug-eluting coronary stent systems used in the treatment of coronary artery disease; percutaneous coronary interventions therapy products to treat atherosclerosis; intravascular catheter-directed ultrasound imaging catheters, fractional flow reserve devices, and systems for use in coronary arteries and heart chambers, as well as certain peripheral vessels; and structural heart therapy systems.

Featured Article: Straddles

Institutional Ownership by Quarter for Boston Scientific (NYSE:BSX)

Receive News & Ratings for Boston Scientific Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Boston Scientific and related companies with MarketBeat.com's FREE daily email newsletter.



Leave a Reply